Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study

Piero Barbanti, Licia Grazzi, Gabriella Egeo, Anna Maria Padovan, Eric Liebler, Gennaro Bussone

Research output: Contribution to journalArticle

Abstract

Background: The treatment of migraine headache is challenging given the lack of a standardized approach to care, unsatisfactory response rates, and medication overuse. Neuromodulation therapy has gained interest as an alternative to pharmacologic therapy for primary headache disorders. This study investigated the effects of non-invasive vagus nerve stimulation (nVNS) in patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM). Findings: In this open-label, single-arm, multicenter study, patients with HFEM or CM self-treated up to 3 consecutive mild or moderate migraine attacks that occurred during a 2-week period by delivering two 120-s doses of nVNS at 3-min intervals to the right cervical branch of the vagus nerve. Of the 50 migraineurs enrolled (CM/HFEM: 36/14), 48 treated 131 attacks. The proportion of patients reporting pain relief, defined as a ≥50 % reduction in visual analog scale (VAS) score, was 56.3 % at 1 h and 64.6 % at 2 h. Of these patients, 35.4 % and 39.6 % achieved pain-free status (VAS = 0) at 1 and 2 h, respectively. When all attacks (N = 131) were considered, the pain-relief rate was 38.2 % at 1 h and 51.1 % at 2 h, whereas the pain-free rate was 17.6 % at 1 h and 22.9 % at 2 h. Treatment with nVNS was safe and well tolerated. Conclusion: Non-invasive vagus nerve stimulation may be effective as acute treatment for HFEM or CM and may help to reduce medication overuse and medication-associated adverse events.

Original languageEnglish
Article number61
JournalJournal of Headache and Pain
Volume16
Issue number1
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Vagus Nerve Stimulation
Migraine Disorders
Therapeutics
Visual Analog Scale
Primary Headache Disorders
Pain
Vagus Nerve
Multicenter Studies

Keywords

  • Acute treatment
  • Disability
  • Migraine
  • Neuromodulation
  • Patient preference
  • Vagus nerve

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine : an open-label study. / Barbanti, Piero; Grazzi, Licia; Egeo, Gabriella; Padovan, Anna Maria; Liebler, Eric; Bussone, Gennaro.

In: Journal of Headache and Pain, Vol. 16, No. 1, 61, 01.12.2015.

Research output: Contribution to journalArticle

@article{3c9d6bb2c52f49e8906d0f0864679265,
title = "Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study",
abstract = "Background: The treatment of migraine headache is challenging given the lack of a standardized approach to care, unsatisfactory response rates, and medication overuse. Neuromodulation therapy has gained interest as an alternative to pharmacologic therapy for primary headache disorders. This study investigated the effects of non-invasive vagus nerve stimulation (nVNS) in patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM). Findings: In this open-label, single-arm, multicenter study, patients with HFEM or CM self-treated up to 3 consecutive mild or moderate migraine attacks that occurred during a 2-week period by delivering two 120-s doses of nVNS at 3-min intervals to the right cervical branch of the vagus nerve. Of the 50 migraineurs enrolled (CM/HFEM: 36/14), 48 treated 131 attacks. The proportion of patients reporting pain relief, defined as a ≥50 {\%} reduction in visual analog scale (VAS) score, was 56.3 {\%} at 1 h and 64.6 {\%} at 2 h. Of these patients, 35.4 {\%} and 39.6 {\%} achieved pain-free status (VAS = 0) at 1 and 2 h, respectively. When all attacks (N = 131) were considered, the pain-relief rate was 38.2 {\%} at 1 h and 51.1 {\%} at 2 h, whereas the pain-free rate was 17.6 {\%} at 1 h and 22.9 {\%} at 2 h. Treatment with nVNS was safe and well tolerated. Conclusion: Non-invasive vagus nerve stimulation may be effective as acute treatment for HFEM or CM and may help to reduce medication overuse and medication-associated adverse events.",
keywords = "Acute treatment, Disability, Migraine, Neuromodulation, Patient preference, Vagus nerve",
author = "Piero Barbanti and Licia Grazzi and Gabriella Egeo and Padovan, {Anna Maria} and Eric Liebler and Gennaro Bussone",
year = "2015",
month = "12",
day = "1",
doi = "10.1186/s10194-015-0542-4",
language = "English",
volume = "16",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine

T2 - an open-label study

AU - Barbanti, Piero

AU - Grazzi, Licia

AU - Egeo, Gabriella

AU - Padovan, Anna Maria

AU - Liebler, Eric

AU - Bussone, Gennaro

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: The treatment of migraine headache is challenging given the lack of a standardized approach to care, unsatisfactory response rates, and medication overuse. Neuromodulation therapy has gained interest as an alternative to pharmacologic therapy for primary headache disorders. This study investigated the effects of non-invasive vagus nerve stimulation (nVNS) in patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM). Findings: In this open-label, single-arm, multicenter study, patients with HFEM or CM self-treated up to 3 consecutive mild or moderate migraine attacks that occurred during a 2-week period by delivering two 120-s doses of nVNS at 3-min intervals to the right cervical branch of the vagus nerve. Of the 50 migraineurs enrolled (CM/HFEM: 36/14), 48 treated 131 attacks. The proportion of patients reporting pain relief, defined as a ≥50 % reduction in visual analog scale (VAS) score, was 56.3 % at 1 h and 64.6 % at 2 h. Of these patients, 35.4 % and 39.6 % achieved pain-free status (VAS = 0) at 1 and 2 h, respectively. When all attacks (N = 131) were considered, the pain-relief rate was 38.2 % at 1 h and 51.1 % at 2 h, whereas the pain-free rate was 17.6 % at 1 h and 22.9 % at 2 h. Treatment with nVNS was safe and well tolerated. Conclusion: Non-invasive vagus nerve stimulation may be effective as acute treatment for HFEM or CM and may help to reduce medication overuse and medication-associated adverse events.

AB - Background: The treatment of migraine headache is challenging given the lack of a standardized approach to care, unsatisfactory response rates, and medication overuse. Neuromodulation therapy has gained interest as an alternative to pharmacologic therapy for primary headache disorders. This study investigated the effects of non-invasive vagus nerve stimulation (nVNS) in patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM). Findings: In this open-label, single-arm, multicenter study, patients with HFEM or CM self-treated up to 3 consecutive mild or moderate migraine attacks that occurred during a 2-week period by delivering two 120-s doses of nVNS at 3-min intervals to the right cervical branch of the vagus nerve. Of the 50 migraineurs enrolled (CM/HFEM: 36/14), 48 treated 131 attacks. The proportion of patients reporting pain relief, defined as a ≥50 % reduction in visual analog scale (VAS) score, was 56.3 % at 1 h and 64.6 % at 2 h. Of these patients, 35.4 % and 39.6 % achieved pain-free status (VAS = 0) at 1 and 2 h, respectively. When all attacks (N = 131) were considered, the pain-relief rate was 38.2 % at 1 h and 51.1 % at 2 h, whereas the pain-free rate was 17.6 % at 1 h and 22.9 % at 2 h. Treatment with nVNS was safe and well tolerated. Conclusion: Non-invasive vagus nerve stimulation may be effective as acute treatment for HFEM or CM and may help to reduce medication overuse and medication-associated adverse events.

KW - Acute treatment

KW - Disability

KW - Migraine

KW - Neuromodulation

KW - Patient preference

KW - Vagus nerve

UR - http://www.scopus.com/inward/record.url?scp=84933529159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933529159&partnerID=8YFLogxK

U2 - 10.1186/s10194-015-0542-4

DO - 10.1186/s10194-015-0542-4

M3 - Article

AN - SCOPUS:84933529159

VL - 16

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 1

M1 - 61

ER -